Regulatory context
Regulatory context; not efficacy evidence
No matched controlled clinical study of this exact preparation was verified in this source audit.
Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Related-compound evidence is contextual only. Commercial names, modifications and routes do not establish clinical equivalence.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Lab or animal research
Modified Thymosin Alpha 1 Distributes and Inhibits the Growth of Lung Cancer in Vivo.
LLC-bearing mice (nine per group) and H460 xenograft mice (seven per group); no treated humans.
Reported findings. Later tumor-growth inhibition and tumor-homing/immune-marker changes were reported.
Nonresponse. LLC tumor volumes did not differ initially during the first three days.
Harms. No obvious body-weight loss was observed; this limited observation does not establish human safety.
Limits. Four-glycine linker is part of the original construct and cannot be silently omitted from preparation identity. Labelled intravenous distribution does not establish the efficacy or safety of intravenous treatment or a commercial preparation.
Preparation: Experimental TA1-GGGG-RGDR synthesized by Apeptide Shanghai; catalog linker and terminal chemistry unverified. Route: Subcutaneous mouse efficacy experiments; separate intravenous FITC-labelled biodistribution experiments are not the same route/effect.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.